Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stop selling and flipping guys and we will be just fine. NSAV.
I say it did. Can you proof otherwise?
It's not a tweet, it's an official NSAV PR.
NSAV ACQUIRES STAKE IN BQEX CRYPTO EXCHANGE AND OVER 4 MILLION REGISTERED USERS, FURTHER EXPANDING PRESENCE IN $2 TRILLION GLOBAL CRYPTOCURRENCY MARKET
Press Release | 01/27/2022
London, England, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Net Savings Link, Inc. (OTC Pink: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that the Company has completed its acquisition of a significant 10% stake in leading cryptocurrency exchange, BQEX Ltd https://bqex.ltd/, and thereby closing NSAV’s largest transaction since its entrance into the $2 trillion global cryptocurrency market. BQEX Exchange has over 4 million registered users and is owned and operated by Metaverse Network LLC. (MNC) https://metaversenetwork.llc/. Based on published reports placing a $95.00 value on each registered user, 4 million registered users would value BQEX Crypto Exchange at an estimated $380 million, and therefore value NSAV’s 10% stake at an estimated $38 million.
Sometimes I'm under impression that somebody just plugs NSAV's logo into all of these. I will not believe anything as long as JT is in charge. NSAV.
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
Press Release | 01/25/2022
Jackson Center, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Greetings From The CEO And Staff At HALBERD CORPORATION (OTC Pink: HALB)!
First of all, I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year!
2021 OVERVIEW AND ACHIEVEMENTS
Halberd continued its R&D strategy to focus on biomedical areas where:
There is a huge worldwide demand for cures to long standing diseases;
There is no effective cure available;
Big Pharma had either failed to meet that demand or had effectively abandoned the effort; and
Halberd's patent position insured high potential of technical and market success.
Halberd chose neurodegenerative diseases as its primary focus, since there are approximately 36 million people cumulatively suffering from PTSD/ CTE, Alzheimer's Disease, Lou Gehrig's Disease, Parkinson's Disease, and Epilepsy in the USA alone. The total worldwide is proportionately much higher.
Halberd's corporate strategy was defined as focusing on completing successful proof-of-concept testing of its patented extracorporeal treatment methodology and subsequently seeking to form joint ventures with Big Pharma organizations and/or university hospital complexes worldwide to secure adequate funding for completion of development testing and regulatory approval prior to market introduction.
Halberd identified three antigens (Tau, Phosphorylated Tau, & Beta Amyloid), six inflammatory cytokines (IL-1, IL-2, IL-4, IL-6, IL-12, and TNF-Alpha) and one excitatory neurotransmitter (Glutamate) as linked to neurodegenerative diseases; later classified as Halberd's "Top Ten Target Antigens."
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7041/111450_4a918ab6a49d9889_001full.jpg
Top Ten Neurological Pathogens
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7041/111450_4a918ab6a49d9889_001full.jpg
Halberd developed a proprietary process to conjoin metallic nanoparticles to proprietary antibodies, forming a two-part metallic moiety. After joining the metallic moiety to the antigens, eradication of the antibody-antigen complex is accomplished via laser emissive energy or radio frequency exposure.
Halberd successfully completed work on eradicating 100% of all eight of the Top Ten target antigens tested so far linked to neurodegenerative diseases. Eradication of Halberd's remaining two Target Antigens has been delayed by lack of availability of commercial reagent supplies from worldwide sources.
The principal competitive Alzheimer's drug treatment available today eliminates 5-15% of Beta Amyloid after one month of treatment costing over $50,000 per year. Halberd's extracorporeal process eradicates 100% within just 10 minutes.
Meetings have been held with representatives from the NFL Retired Players Association (NFLPA) to develop a strategy for presenting our results to NFL management to seek their support for ongoing research toward developing a cure for PTSD/CTE. Meetings have not yet been established with NFL management.
Halberd added an expert Nephrologist to its staff in anticipation of blood-borne tests, slated to get underway after completion of testing in cerebral spinal fluid (CSF).
One issued patent has been added this year to Halberd's IP for the extracorporeal treatment of disease, bringing the total to three related issued patents. Additionally, Halberd added several provisional patent applications bringing that total to twenty. Halberd is working hard to protect its intellectual property to prevent potential theft and/or duplication by competitors.
Halberd Corp. commenced an independent audit in the fourth quarter to work towards its planned FORM-10 application to achieve fully reporting status with the SEC under the Exchange Act of 1934.
Halberd has been approved as a governmental contractor making it eligible to participate in development grants, and is currently awaiting a decision on such a potential large government grant associated with PTSD/CTE.
FORWARD GOALS
Halberd's on-going independent audit is anticipated to be completed within Q1 2022.
Efforts are underway on filing Halberd's FORM-10 contingent on the completion of its independent audit leading to OTCQX exchange up-list by or within Q2 2022.
Completion of the Top Ten Target Antigen elimination from CSF is expected to be completed within Q1 2022.
Establish and execute meetings with the NFL and possibly the NCAA to seek endorsement for Halberd's PTSD/CTE research.
Halberd plans on further expanding brand recognition and outreach by communicating with investors and the public via appearances on New-To-The-Street, Money TV, Stock Day Podcast along with periodic press releases and email blasts to our subscribers to provide visibility on our progress.
Discussions have commenced and are in progress with a large medical university to develop potential cures for several neurodegenerative diseases with potential independent validation within the year 2022. We plan on sharing the name of this university once an agreement is established.
We are looking into conducting initial discussions with an identified pharmaceutical company for potential partnering arrangements.
The next steps in Halberd's R&D program include eradication of the "Top Ten Target Antigens" from blood elements (serum and plasma).
Plans are underway for generating scientific articles for publication within Q1 2022. The material will be carefully screened for patentable content prior to publication to protect our intellectual property and achievements.
Halberd is currently searching for an infectious disease specialist to be added to its company staff within Q1 2022 to assist in developing and testing cures for infectious diseases which have the potential of being treated with Halberd's proprietary technology.
Halberd plans to expand its over-the-counter (OTC) supplement product line with a brain function support product. The brain function support product is currently being formulated and designed. We plan on sharing updates as we progress.
Halberd will continue its efforts in developing relationships toward placing and marketing its nutraceutical line products in both Central and South America to increase both brand recognition and revenue.
Conclude current ongoing talks with a major university to acquire related abandoned intellectual property that could expand Halberd's value significantly.
Continue to protect Halberd's intellectual property by timely filing of patent applications.
SUMMARY
In summary, the Halberd team is expanding its technical capabilities and has exhibited solid progress in 2021. We believe our strategy going forward is exciting and will lead to success for the company and our stockholders/shareholders in 2022 and beyond.
We look forward to a healthy, happy and prosperous 2022 for all.
Sincerely,
William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (the "Company") is an innovative biotech company focused on developing treatments through its acquired exclusive licenses, patents, and provisional patent applications for illnesses including and limited to; PTSD, CTE, cancer, blood-borne, and cerebrospinal fluid related diseases. To learn more, please visit https://halberdcorporation.com.
Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
https://www.otcmarkets.com/stock/HALB/news/Halberd-CEO-Letter-2021-Year-End--2022-Outlook?id=340541
Funny to see you guys still in tranches. SIPC. GLTYA.
Totally agree. No doubts in my mind.
Thank you for working so late from the rest of us. NSAV.
Didn't we see about like this yesterday?
I like the wisdom in your posts, keep doing it. NSAV/GLTY.
And that may not be the answer. The correct answer IMO could be "who knows."
Flippers and multimil's.
Opportunity is here for somebody who wants to see it. NSAV.
Meta is not going to lose but will become crypto leader. Together with NSAV! GLTA!!!
GOLD KICKS FOR SOLIDGOLD IN FROZEN TUNDRA!!! Everything is possible!!! $$$NSAV$$$
NSAV is by far one of the better looking crypto on my list. GLTA.
Just a balancing act.
Link is attached, in the sticky and in yesterday's PR.
https://www.otcmarkets.com/stock/NSAV/news/NSAV-TO-ACQUIRE-SIGNIFICANT-MINORITY-STAKE-IN-BQEX-CRYPTO-EXCHANGE-OVER-4-MILLION-REGISTERED-USERS?id=339973
Or will be better?
W. Y. Cheung, CEO of MNC stated, "We are very excited to be working with the management team of NSAV. We are very impressed with the advanced technical ability of the NSAV team. They are very blockchain savvy and their vision has always enlightened me.”
Dato’ Sri Desmond Lim, Interim CEO and Senior Vice President of Cryptocurrency Operations for NSAV and Silverbear Capital partner stated, “This is another major step in accelerating the strategy of NSAV and building a global community to aggregate our ECOsystem to the next tier. I am thrilled that we are continually commercializing the relationship between NSAV and Metaverse Network.”
https://www.otcmarkets.com/stock/NSAV/news
Don't feel so bad, and another 40 and 10+ % purchases will be coming. NSAV is building UP.
Flippers will start jumping pretty soon. NSAV.
I think comparable market value for NSAV is just fine .... for now. But we need more order, mor official record keeping and a new REAL CEO. JMO.
NSAV TO ACQUIRE SIGNIFICANT MINORITY STAKE IN BQEX CRYPTO EXCHANGE, OVER 4 MILLION REGISTERED USERS
Press Release | 01/20/2022
London, England, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Net Savings Link, Inc. (OTC Pink: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that the Company will acquire a 10% stake in cryptocurrency exchange, BQEX Ltd. https://bqex.ltd/. BQEX Exchange has over 4 million registered users and is owned and operated by Metaverse Network LLC. (MNC) https://metaversenetwork.llc/. MNC anticipates going public in New York in Q1, 2022.
Mfaphoto I'm with you and totally agree with your vision on $$$NSAV$$$. GLTY my friend.
We need help from anywhere we can get it. I agree we need closing of the deals being announced so far. And we need to delay flippers for a while. NSAV.
You think so? I hope so. Still big sales on low volume with today's repeated results.
I also think that BW deal is just one of many NSAV is trying to accomplish moving step by step forward. Big guns are here to make $$$$.
I can still see us in NSAV $ 2-3 PPS in time and full execution.
Still somebody is selling big numbers. NSAV.
I'm waiting for this Victory Day with huge anticipation. GLTA.
All info is on OTC markets.
EXACTLY.
Very low volume. NSAV needs more exposure and oriental investors. IMO.
All is still quiet on the RSHN front.
Net Saving Link (OTCMKTS:NSAV) Stock Sees Buying Interest At Lower Level: But Why?
Posted By Cody Martinez on January 17, 2022
Net Saving Link (OTCMKTS:NSAV) stock surged on January 13, 2022, after the firm announced a fresh deal with Meta stock is rising higher on Friday after the company announced a new deal with Metaverse Network. The company confirmed on acquiring a 10% stake in Metaverse Network and both companies are a part of the crypto sector with a focus on blockchain.
Trading Data
On Friday, NSAV stock increased 4.78% to $0.0219 with more than 19.80 million shares traded, compared to its average volume of 36.47 million shares. The stock has moved within a range of $0.0205 – 0.0230 after opening trading at $0.0210.
Latest Development
Metaverse Network operates the BQEX Exchange and it currently has about 4 million registered users. Net Saving Link has confirmed that investment will boost its presence in the $500 million Metaverse market. Furthermore, it also said that Metaverse Network may go public soon by listing on New York Stock Exchange by quarter one of 2022.
It is also possible that NSAV may witness investment in Metaverse stock surge in value. The collaboration between the two firms will enable them to launch a pioneer NFT with NSAV getting between 5% to 7.5% of the tokens.
W. Y. Cheung, CEO of Metaverse Network said that the company is excited about working with NSAV management, as it is blockchain savvy and has an impressive vision. The firm’s stock was by 7.7% on January 14, 2022. The collaboration between the firms will help launch an NFT with NSAV receiving 5 to 7.5% of the tokens.
Technical Data
NSAV stock is below the 20-Day and 50-Day Moving averages of $0.0247 and $0.0304 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0290.
https://topnewsguide.com/2022/01/17/net-saving-link-otcmktsnsav-stock-sees-buying-interest-at-lower-level-but-why/
It's clear as a bright day. NSAV.
YES!!!
Ronnie Lott, we could use him today (Raiders ) and tomorrow ( 9'rs ). The main thing in common we have are NSAV projects. I'm deep in my retirement and all in. Sitting here in Silicon Valley I'm a believer. You are making some very solid points and I like your postings. I'm just out of Covid, feeling better. Stay HEALTHY. $$$$NSAV$$$
Right before covid in 2020 we visited Montreal, Quebec, Ottawa, Toronto and Niagara canadian side. Love it all! Was my number 1 place to visit. But staying in my SFR bay area for many years now. GO SHRKS! :)